Navigation Links
Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
Date:8/20/2009

VANCOUVER, Aug. 20 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in June and a limited pre-launch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as announced in March 2008.

"The pre-launch of the Option IVC Filter last month was overwhelmingly successful, demonstrating its potential to be a market leading product in pulmonary embolism prevention," said Dr. William Hunter, President and CEO of Angiotech. "We are excited to announce that the Option IVC Filter is now available throughout the U.S. through our dedicated Interventional Sales team."

The Option IVC Filter is used for the prevention of recurrent pulmonary embolism (PE). The device is implanted, typically by Interventional Radiologists in a minimally invasive procedure, into the body's inferior vena cava to prevent PE. The Option IVC Filter is specifically designed for use as both a permanent or temporary implant (in temporary, or retrievable, indications, a physician may later perform a second surgical procedure to remove the Option IVC Filter if necessary or where mandated clinically).

About the Option(TM) Inferior Vena Cava Filter

The Option IVC Filter, developed by Rex Medical, is specifically designed to facilitate long-term retrieval post device implantation if desired or deemed necessary by the treating physician, and can be used in the following conditions: pulmonary thromboembolism when anticoagulant therapy is contraindicated, failure of anticoagulant therapy in thromboembolic diseases, emergency treatmen
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
2. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
3. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
4. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
5. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
6. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
7. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
8. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
9. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
10. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
11. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 The chemistry, taste, and health effects of ... article published by the nonprofit American Botanical Council (ABC). Recent ... and its effects on the phytochemical compounds in tea ( ... by Dr. Ahmed in the Yunnan ... implications for the future of medicinal botanicals. Dr. Ahmed,s ...
(Date:9/15/2014)... 15. September 2014 Die zweite jährliche ... vom 12. bis 18. Oktober stattfinden. Die IPAW ... Therapeutics Association (PPTA) und ihrer Mitgliedsunternehmen ... Das globale Bewusstsein für die Gewinnung von Quellplasma ... beim Retten und Verbessern von Leben zu würdigen ...
(Date:9/15/2014)... , 15 de septiembre de 2014 La segunda ... a cabo del 12 al 18 de octubre. Como iniciativa ... y de sus compañías miembro s, la IPAW se ... mundial en torno a la colección de fuentes de plasma ... plasma al salvar y mejorar las vidas , Aumento ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Hydro ... ) announced today that it will be partnering ... CA ( http://www.proteaf.com ) for implementing its Shock ... value continuous processing. Continuous flow chemistry through ... chemical, pharmaceutical and petrochemical markets for decades. ...
Breaking Biology Technology:Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3La International Plasma Awareness Week será una celebración para los donantes 2La International Plasma Awareness Week será una celebración para los donantes 3Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2
... Ohio -- In the quest for smaller, faster computer ... the exotic physics of the small. The problem: ... been equally exotic. That is, until now. ... to make quantum devices using technology common to the ...
... 15 Today, Formatech, Inc. announced that ... HIV/AIDS vaccine will be the first clinical candidate that is ... run is scheduled to be completed in January 2010. ... aseptically fill and finish one lot of the vaccine for ...
... 15 SIRO Clinpharm, a global Contract Research Organization (CRO) ... announced expansion of its Clinical Trials Supplies facility in Mumbai, ... pharmaceutical and biotech companies for storage and distribution of clinical ... , "We opened our clinical trials supplies warehouse ...
Cached Biology Technology:Quantum computer chips now 1 step closer to reality 2Quantum computer chips now 1 step closer to reality 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 2Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 3Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its 'Fillanthropy(TM) Program' 4SIRO Clinpharm Strengthens its Clinical Trials Supplies Service Offering in India 2
(Date:9/15/2014)... Globally, cardiovascular disease (CVD) claims 17 million lives each ... additional 9.4 million. 1 New research presented by ... in Montpellier, France on September 15, 2014, suggests that ... , At the Milk and Dairy Products ... and risk for hypertension and CVD was examined by ...
(Date:9/15/2014)... the need for vitamin E and how much is ... levels of this essential micronutrient are especially critical for ... or may become pregnant. , A lifelong proper intake ... often complicated by the fact that this nutrient is ... alone. It has been estimated that only a tiny ...
(Date:9/12/2014)... DUBLIN, Ireland , September 12, 2014 ... and Markets ( http://www.researchandmarkets.com/research/trs4c7/global ) has announced ... Lock Industry Report 2014" report to ... Fingerprint Lock Industry Report 2014 is a ... state of the global fingerprint lock industry. ...
Breaking Biology News(10 mins):Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2Vitamin E intake critical during 'the first 1,000 days' 2Vitamin E intake critical during 'the first 1,000 days' 3Global Fingerprint Lock Industry Report 2014 2
... Spanish . Losses of managed honey bee ... 2009 to April 2010, according to a survey conducted by ... Service (ARS). Beekeepers identified starvation, poor weather, and weak colonies ... their operations. This is an increase from overall losses ...
... cognitive decline and for preventing Alzheimer,s diseasemental stimulation, ... studied over the years. However, an independent panel ... Health determined that the value of these strategies ... of decline or disease hasn,t been demonstrated in ...
... research team has taken a major step forward in understanding ... immune response by combining nanotechnology and cell biology. T cells ... response to infection. Christopher Cairo and his team ... cell response is switched on. Cairo looked at the molecule ...
Cached Biology News:Survey reports latest honey bee losses 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 2Panel finds insufficient evidence for Alzheimer's disease preventive measures 3U Alberta-led team studies T cell activation with nanoparticles 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: